Table 1.
Baseline Characteristics by Treatment Group
| Characteristic | Total Cohort, n = 1,547 | No Reversal, n = 454 | FFP Only, n = 377 | PCC Only, n = 585 | FFP + PCC, n = 131 | p |
|---|---|---|---|---|---|---|
| Age, yr | 77 (70–83) | 78 (71–84) | 78 (71–83) | 77 (70–82) | 76 (68–84) | 0.159 |
| Male sex | 884 [57] | 239 [53] | 217 [58] | 342 [58] | 86 [66] | 0.045 |
| GCS at admission | 13 (8–15) | 12 (5–15) | 13 (6–15) | 14 (11–15) | 14 (13–15) | <0.001 |
| Baseline blood glucose, mg/dla | 141 (115–175) | 152 (119–191) | 139 (112–172) | 137 (114–166) | 141 (116–178) | 0.001 |
| Baseline ICH volume, ml | 18 (6–52) | 28 (7–79) | 16 (5–52) | 15 (5–40) | 18 (6–34) | <0.001 |
| Infratentorial location | 272 [18] | 77 [17] | 59 [16] | 106 [18] | 30 [23] | 0.288 |
| Intraventricular extension | 757 [49] | 241 [53] | 203 [54] | 263 [45] | 50 [38] | <0.001 |
| Baseline IVH volume, mla | 0 (0–8) | 0 (0–25) | 0 (0–11) | 0 (0–5) | 0 (0–3) | <0.001 |
| INR at admission | 2.9 (2.4–3.7) | 2.8 (2.2–3.7) | 2.9 (2.3–3.5) | 3.0 (2.5–3.8) | 2.9 (2.4–3.5) | 0.024 |
| Onset‐to‐treatment, mina | 305 (175–660) | — | 340 (203–630) | 285 (165–625) | 355 (185–845) | 0.077 |
| Acute intracranial surgery | 144/1,536 [9] | 14/449 [3] | 37/377 [10] | 73/580 [13] | 20/130 [15] | <0.001 |
| Received vitamin K | 1,024/1,477 [69] | 137/451 [30] | 330/366 [90] | 434/530 [82] | 123/130 [95] | <0.001 |
All values are median (interquartile range) or No. [%].
a
Data for glucose/IVH volume/onset‐to‐treatment time missing in 156/217/0 of no reversal, 43/47/305 of FFP, 124/111/188 of PCC, and 46/7/6 of FFP + PCC patients, respectively.
FFP = fresh frozen plasma; GCS = Glasgow Coma Scale; ICH = intracerebral hemorrhage; INR = international normalized ratio; IVH = intraventricular hemorrhage; PCC = prothrombin complex concentrate.